AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026 Autolus’s Jefferies investor appearance in London Headline · Source: company release
Nasdaq Global Select Market · $AUTLCell therapyCommercial leukemia productClinical and financing risk

AUTL Stock Hub: Autolus Therapeutics News, AUCATZYL and Lupus Trials

Autolus has an approved leukemia treatment and a growing commercial business. September-quarter AUCATZYL sales reached $41.238 million with a 57% gross margin, while the company continued to use cash in operations. The question is whether more completed treatments and lower manufacturing costs can fund the next indications, including investigational use in lupus nephritis, before the company needs more capital. September Form 10-Q · Quarterly results · U.S. approval.

Last updated: November 19, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars unless stated otherwise
Full research report · PDF
Autolus Therapeutics plc ($AUTL), research updated November 19, 2026
20 pages on AUCATZYL, leukemia and lupus, royalty obligations, cash and financing. For personal use only: redistribution prohibited.
Get the report (PDF)
Next scheduled clinical presentations
December 12, 2026 · American Society of Hematology (ASH) Annual Meeting

An oral presentation examines the first three months after treatment in the adult leukemia trial. A separate poster reports early observations from ALARIC in light-chain amyloidosis. Autolus meeting announcement · Official program for the leukemia presentation.

The meeting runs December 12–15 in New Orleans. Autolus announced publication of the abstracts on November 4. Meeting calendar.

Autolus Therapeutics plc AUTL daily stock chart
Daily chart $AUTL. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

AUTL stock at a glance

Chart analysis · JC
Technical chart analysis of $AUTL with bull and bear scenarios on JC Just Charts.
Cash and marketable securities
$248.4 million
September 30, 2026. Company results.
Product sales outlook
$150 million or more
Company forecast for full-year 2026, November 10. Revenue outlook.
Operating cash use
$108.918 million
Nine months ended September 30, 2026. Statement of cash flows.
Senior secured note principal
$75 million
Initial tranche funded July 30. Credit agreement disclosure.
Ordinary shares outstanding
266,340,330
November 9, 2026. Each American depositary share (ADS) represents one ordinary share. Cover of Form 10-Q.
Short interest
8,628,641 shares
October 30, 2026 settlement. Nasdaq data.

Where Autolus stands now

AUCATZYL is marketed for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in the United States and United Kingdom. The same therapy, obecabtagene autoleucel or obe-cel, is being tested separately in autoimmune diseases and younger patients. Revenue today comes from the approved leukemia indication. Those expansion programs require their own evidence and carry costs before any new commercial use can begin. U.S. authorization · Operations and clinical programs.

Product demand and access to financing interact. The November operating outlook includes anticipated product revenue and $100 million from the first two Perceptive credit tranches. One tranche was funded in July. Autolus’s option to draw the second tranche has a contractual deadline. Revenue tests apply to the two additional tranches. Management’s November runway forecast · Credit terms and September balances.

Constructive case

Established treatment centers treat more eligible patients, and Autolus collects more cash from its distributor. Higher output improves the economics of each treatment and gives Autolus room to fund trials in new indications.

Cautious case

Referral and reimbursement friction slow completed treatments. The company must continue financing a specialist manufacturing network and longer clinical programs while complying with credit covenants.

Latest AUTL news

Nov 17, 2026

Autolus’s Jefferies investor appearance in London

Autolus listed a November 17 appearance by Chief Executive Officer Christian Itin during the Jefferies Global Healthcare Conference. Its November results and corporate presentation provide the latest period figures and operating outlook.

Nov 16, 2026

MAK and Armistice disclose September Autolus ownership

Two Schedule 13G amendments filed November 16 reported September 30 positions of 30,528,859 ADSs, or 11.5%, for the MAK reporting group and 13,750,000 ADSs, or 5.17%, for the Armistice reporting group. Positions within each group overlap across reporting persons.

Nov 13, 2026

Autolus registers plan shares and CATULUS record is updated

Autolus registered 10,653,613 ordinary shares represented by ADSs for incentive-plan capacity. Separately, the public CATULUS study record was updated and lists recruitment.

Nov 12, 2026

Qatar Investment Authority and Syncona report Autolus holdings

Qatar Investment Authority reports 9,184,404 Autolus ADSs, or 3.5%, and says it ceased to own more than five percent. Syncona separately reports a 9.2% fully diluted interest. Both figures are dated September 30 and use different share-count bases.

AUTL catalyst calendar

  • July 30, 2026 — Autolus closed the Perceptive facility and drew the first tranche. Completed financing · August Form 8-K on the July closing
  • September 9, 2026 — Autolus announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation in systemic lupus erythematosus and lupus nephritis. Development designation · Company announcement
  • September 22, 2026 — The prospectus covered potential resale of shares underlying the initial Perceptive warrant. Resale registration · Form 424B3
  • November 3–4, 2026 — Autolus announced inducement awards and publication of abstracts for the ASH Annual Meeting. Company disclosures · Equity awards · ASH preview
  • November 6, 2026 — Blackstone’s warrant expired without exercise. Contractual expiry · September Form 10-Q, Note 16 · November 10 Schedule 13D amendment
  • November 10, 2026 — Autolus filed its September Form 10-Q, reported results and presented longer CARLYSLE follow-up at the American College of Rheumatology (ACR) meeting. Quarterly filing, results and clinical presentation · Form 10-Q · Results exhibit · CARLYSLE update
  • November 12–13, 2026 — Qatar Investment Authority filed an amended Schedule 13G reporting 9,184,404 ADSs, or 3.5%, below the 5% reporting threshold. Syncona reported its September holding. Autolus registered additional incentive-plan shares, and the pediatric CATULUS study record was updated. Ownership, registration and trial record · Schedule 13G amendment · Form S-8 · CATULUS registry · Syncona interim disclosure
  • November 16–17, 2026 — MAK Capital and Armistice filed ownership amendments on November 16. Chief Executive Officer Christian Itin was scheduled to speak at Jefferies in London on November 17. Ownership filings and past investor event · MAK · Armistice · Event announcement
  • December 12, 2026 — The meeting program includes the ALARIC poster and an oral presentation on adult leukemia follow-up from FELIX. Scheduled clinical presentations · Company abstracts · ASH oral program
  • December 14, 2026 — Another presentation examines low disease burden and leukemia outcomes using observational data. A separate poster studies two monitoring methods after obe-cel. Scheduled scientific presentations · ASH session · Monitoring abstract
  • January 1, 2027 — Autolus expects U.S. domestic issuer requirements to take effect after losing foreign private issuer status. Company disclosure on regulatory status · Risk factors and reporting dates
  • January 30, 2027 — The availability window for the optional second credit tranche ends under the agreement. Contractual date · Form 10-Q, Note 14
  • October 2027 — Autolus plans to present first BOBCAT data in progressive multiple sclerosis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress. Company presentation window · Revised study timeline · Congress dates
  • By year-end 2027 — Autolus expects data from the Phase 2 portion of CATULUS in pediatric leukemia. Company guidance · Clinical timeline
  • 2028 — Autolus expects LUMINA results in refractory lupus nephritis. Company guidance · Clinical timeline · Study registry

How the commercial and clinical milestones fit together

More completed treatments

The number of authorized centers describes availability. Completed courses and collections determine whether growth supports operating cash flow. Treatment delivery and revenue recognition.

Evidence for additional uses

Adult leukemia has regulatory approval and a commercial distribution network. Lupus, pediatric disease and other programs have their own trial populations and outcome measures. Lupus results · Further clinical programs.

Autolus Therapeutics plc deep dive: the full analysis

The chapters cover AUCATZYL’s adoption and costs, the evidence in leukemia and autoimmune diseases, and the obligations that affect the cash available to pursue those indications. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios for a commercial cell-therapy company

Bull scenario · Higher treatment throughput supports development

More centers turn referrals into treatment and established centers use the product more consistently. Production gains improve the margin without relying on temporary relief from materials previously expensed. As cash collections improve, Autolus has more discretion over which new studies to pursue internally and which to develop with partners. Larger renal studies with durable responses and acceptable safety would provide a separate development opportunity in a group with few remaining options.

Base scenario · The launch grows, with financing still contributing

Commercial activity improves alongside manufacturing utilization, but revenue varies by quarter because treatment is personalized. Interest, revenue sharing and operating costs keep pressure on cash. The optional tranche helps fund the current plan and late clinical readouts require continued development spending. The key question remains how much incremental gross profit is left for research and operating expenses after delivering the therapy.

Bear scenario · Revenue growth arrives too slowly for the facility assumptions

Hospitals refer fewer patients than expected, approval of coverage takes longer or patients cannot remain eligible through treatment. With slower volume growth, Autolus has fewer treatments over which to spread fixed manufacturing costs. Service delays or clinically important adverse events can put further pressure on physician adoption. If revenue weakens, cash conversion can deteriorate in the same period that further borrowing becomes harder to access. Operating and financing risks.

What would falsify this reading

If the treatment network grows but the company continually reports weaker product revenue and increasing costs per treatment, the idea that center expansion and utilization can improve operating economics loses support. A substantial working-capital build accompanied by weaker collections would have a similar effect even if reported sales rise. Repeated weakness in liquidity near covenant measures would matter for funding future programs. Revenue, cost of sales and financing covenants.

The view of lupus as a plausible expansion depends on meaningful kidney outcomes lasting through follow-up with tolerable safety. If patients relapse as B cells recover, require more rescue therapy or experience severe complications on wider enrollment, a short-term renal response would have less value. Consistent and durable outcomes from LUMINA would shift attention to patient selection, regulatory requirements and how specialist centers could deliver the product outside its existing oncology market. CARLYSLE follow-up · LUMINA registry.

02 From patient referral to recognized revenue

Autolus Therapeutics plc is incorporated in England and Wales and sells a cell therapy made from a patient’s own immune cells. AUCATZYL is a chimeric antigen receptor (CAR) T-cell therapy directed at CD19, a protein found on malignant and normal B cells. In the approved leukemia setting, that targeting is used to attack disease that returned or did not respond adequately to previous treatment. The care pathway requires a specialist team, patient-specific manufacturing and observation for adverse reactions. The number of eligible patients is therefore distinct from the number who can complete treatment in a given quarter. U.S. prescribing information · Company operating overview.

The Form 10-Q describes Cardinal Health as the company’s agent in the United States. Authorized treatment centers accept the product and administer it. The filing says Cardinal Health pays Autolus after delivery and acceptance at the center under standard payment terms. The center pays Cardinal on delivery and acceptance and can receive a credit in specified circumstances when the patient does not receive one or both doses. Autolus treats the patient as the customer for accounting purposes. It recognizes revenue when it satisfies its single performance obligation, upon administration of the final dose. It records a receivable when the product sale is invoiced and administration is complete. An order or a manufactured batch can therefore use resources before the product contributes to recognized sales. Revenue recognition policy and U.S. distribution.

Autolus’s November presentation showed 90 authorized U.S. treatment centers. It identified rising demand within existing sites, additional centers and sales in the United Kingdom as drivers. A site on that list can create geographical access and referral opportunities. Demand within sites depends on clinicians having eligible patients, attention to safety, and the ability to schedule treatment in time. Growth can therefore come through more volume at experienced sites even after the company reaches its target for opening new centers. November 10 presentation, slides 4 and 5.

Gross-to-net deductions matter even after a course is completed. September accruals for rebates and chargebacks totaled $11.291 million, compared with $4.991 million at year-end 2025. Note 3 reports new accruals, payments and credits, and revisions related to prior periods. Those balances can change as billing experience and payer terms evolve. Collections and contractual deductions give additional information about the launch that the center count alone cannot capture. Note 3 product revenue and deduction rollforward.

03 Three regulatory markets, different commercial paths

The FDA approved AUCATZYL in the United States on November 8, 2024, for adult patients with relapsed or refractory B-cell precursor ALL. Autolus recorded its first U.S. sale in January 2025. The FDA’s February 26, 2026 supplemental approval revised several parts of the U.S. label, including warnings, administration and information on immune responses to treatment. The approval letter describes changes to information for the existing adult leukemia use, so it does not add an autoimmune or pediatric indication. Original FDA approval · Supplemental approval letter · Commercial sales timing.

The United Kingdom granted conditional marketing authorization on April 25, 2025, for adult relapsed or refractory B-cell precursor ALL. In November 2025, the National Institute for Health and Care Excellence (NICE) recommended routine use through the National Health Service (NHS) in patients age 26 and older, subject to the commercial arrangement. The Form 10-Q describes that recommendation as applying in England and Wales. This recommendation has a distinct scope from the licensed adult indication. Autolus recorded its first U.K. sale in January 2026 and describes availability through NHS and private treatment centers. U.K. regulatory authorization · NICE recommendation · U.K. commercial launch.

The European Commission granted conditional marketing authorization on July 17, 2025, for adults age 26 and older with relapsed or refractory B-cell precursor ALL. Autolus GmbH is the holder listed by the European Medicines Agency (EMA). An authorization covering the European Union is followed by country-level market access and commercial decisions. The November filing said Autolus had put its European Union launch, including Germany, on hold while it assessed pricing and the feasibility of entry. It reported no European Union product revenue for 2025 and projected none for 2026. EMA European public assessment report · European market entry update.

In each market, competition includes other therapies and the capacity of the centers that can administer them. NICE discussed brexucabtagene autoleucel for the English population age 26 and older, where it had been available through the Cancer Drugs Fund. The place of a treatment in practice can change as clinicians gain experience, while funding decisions influence the pace at which patients enter the pathway. The data used to support the original approval are several steps removed from those commercial effects. NICE committee discussion · Market access risk factors.

04 Adult leukemia evidence and its limits in practice

B-cell precursor ALL can return after remission or persist despite treatment. The FELIX Phase 1b/2 study enrolled adults with relapsed or refractory disease in an open-label, single-arm design. Roddie and colleagues reported in the New England Journal of Medicine in 2024 that 127 of 153 enrolled patients received at least one infusion. The other 26 included 18 with death or uncontrolled disease before infusion, seven with manufacturing failures and one for whom the physician chose otherwise. The difference between enrollment and infusion is clinically important in a rapidly progressing disease and relevant to the launch. A specialist center needs to keep a patient eligible while arranging a personalized treatment. Roddie et al., New England Journal of Medicine, 2024.

In the 94-person main cohort with morphologic disease, the publication reported 77% overall remission, including 55% complete remission. Overall remission included people who met the complete-remission criteria in the marrow but had incomplete recovery of blood counts. Across all 127 infused participants, the reported median event-free survival was 11.9 months and median overall survival was 15.6 months. These figures describe different clinical measures and, in some cases, different populations within FELIX. Response measures report improvement over a defined window. Overall survival measures time until death. Event-free survival measures time until a prespecified event such as treatment failure, relapse or death. FELIX efficacy analyses and population definitions.

The FDA approval summary used a narrower efficacy population and a defined response window. Of 65 patients in that analysis, 27, or 42%, achieved complete remission within three months. The median duration of that complete remission was 14.1 months. The FDA analysis and the journal’s primary cohort therefore provide complementary views. The former uses complete remission within a fixed window and the latter includes complete remission with incomplete blood count recovery in its main outcome. Neither rate is a direct comparison with another marketed therapy. FDA approval summary and outcome definition · Primary publication.

Safety needs its own denominator. The journal reported grade 3 or higher cytokine release syndrome (CRS) in 2.4% of the 127 infused patients and grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS) in 7.1%. The updated U.S. prescribing information separately describes 100 patients in its safety analysis. Nine of the 100 patients experienced fatal adverse reactions, including infections and neurologic or inflammatory complications. The boxed warning covers CRS, neurologic toxicity and secondary hematological malignancies. The label describes a death from sepsis with unresolved hemophagocytic lymphohistiocytosis or macrophage activation syndrome and a concurrent neurologic event. Specialist monitoring and longer-term follow-up remain material to patients, treatment centers and product adoption. Peer-reviewed study safety · February 2026 prescribing information, sections 5 and 6.

Topp and colleagues reported a matched external comparison in Leukemia in 2026. In the 107-participant FELIX intention-to-treat group matched against historical patients, overall remission was 67.3% for the obe-cel arm and 51.4% for the historical non-CAR T treatment arm. Matching used observed baseline characteristics and the controls came mainly from trials of other therapies, including blinatumomab, inotuzumab ozogamicin and chemotherapy. Differences in treatment era, care pathways or characteristics that were unmeasured can remain after matching. The analysis adds context for use after previous therapies while leaving comparative outcomes to be tested directly. Topp et al., Leukemia, 2026, external comparison.

A separate three-year analysis of brexucabtagene autoleucel in ZUMA-3 provides a second point of reference. Shah and colleagues reported median overall survival of 25.6 months for 78 treated adults at a median follow-up of 41.6 months. A five-year follow-up published on November 5, 2026, reported 40% overall survival at five years among the same 78 participants, at a median follow-up of 65.7 months. Each study had its own eligibility and follow-up. Comparing those medians with FELIX without accounting for disease history, subsequent care and the populations would overstate what the evidence can say about relative performance. For patients and centers, choice also depends on eligibility, ability to deliver the treatment, adverse events and access to care. Shah et al., Leukemia, 2025, ZUMA-3 three-year follow-up · Five-year update, Transplantation and Cellular Therapy, 2026 · FELIX population and follow-up.

Autolus has cited real-world data from the Real World Outcomes Collaborative for CAR T in Adult Acute Lymphoblastic Leukemia (ROCCA) consortium. Autolus reported at its March 2026 results that, in the update presented at the February 2026 Tandem Meetings, the registry covered about 60% of U.S. commercial recipients at its January 5 cutoff. The April presentation identified 96 patients in the cohort, including 91 who received treatment. It reported no high-grade CRS and 3% high-grade ICANS among treated patients. Those findings are observations in patients treated in practice and depend on who was included and how events were captured. The December meeting program includes a separate observational analysis of lower disease burden. Hospital practice data can show how trial experience carries over to routine care, while selection and reporting still affect comparisons across groups. Autolus disclosure on February registry coverage · April presentation on ROCCA · ASH disease burden session.

05 Lupus evidence, kidney response and the next trial

Systemic lupus erythematosus (SLE) can affect multiple organs. Lupus nephritis is kidney involvement and can remain active after conventional treatment. CARLYSLE studies obe-cel in severe refractory SLE. The clinical rationale is that reducing disease-driving B cells could interrupt the immune response implicated in the condition. In patients whose kidney disease is already difficult to control, the value of that approach depends on how long renal and systemic responses persist and whether they reduce the need for additional therapy. ClinicalTrials.gov CARLYSLE record · November 10 study update.

At the August 11, 2026 cutoff for the November CARLYSLE poster, 15 participants had been infused and were evaluable for safety, including 12 adults and three adolescents. Median follow-up was 19 months in the lower-exposure adult cohort, 12.4 months in the other adult cohort and 10.1 months in adolescents. Some adult follow-up extended to 25.5 months. Two-thirds of the infused population had class III or IV lupus nephritis, with or without class V. The registry lists 16 enrolled participants and the company presentation identifies the 15 treated by its cutoff. Enrollment and infusion describe different steps in a small study. Company clinical report · November ACR abstract · Registered enrollment.

Autolus reported that all patients with at least six months of follow-up in the November analysis reached Definition of Remission in SLE (DORIS) remission. Six of nine in that follow-up group achieved a complete renal response at some point after infusion. Another participant reached a partial renal response beginning at month seven, and the company reported no severe renal flares. The definition of overall lupus remission can allow stable background treatment under specified conditions. A renal response occurring at any measured visit is also a different test from a response assessed at a specified month. Patient-level treatment requirements and repeat assessments will matter to the interpretation of durability. Response denominators in the November disclosure · 2021 international remission definition.

Autolus reported no ICANS, hemophagocytic lymphohistiocytosis or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), and no grade 3 or higher CRS in the November safety group. The earlier December 2025 update reported one transient grade 3 liver toxicity in the higher-exposure cohort. A small Phase 1 population gives information about observed tolerability but has limited power to characterize uncommon events. An observed absence in one group, especially with varied follow-up, still leaves uncertainty about later events and risks in a larger population. November 2026 safety update · December 2025 clinical and safety report.

Other cell therapies provide clinical context for the approach. Mackensen and colleagues reported in Nature Medicine in 2022 that five people with refractory SLE achieved DORIS remission by three months in a compassionate-use series. Müller and colleagues reported in the same journal in 2026 that nine of ten lupus participants in the CASTLE basket study reached DORIS remission at 24 weeks. CASTLE treated several autoimmune diseases and used a different product, zorpocabtagene autoleucel. These studies show that responses have been observed in other early studies of CD19-targeted cell therapy. Their design and treatment populations differ from CARLYSLE and they do not provide a direct comparison with obe-cel. Mackensen et al., Nature Medicine, 2022 · Müller et al., Nature Medicine, 2026.

LUMINA is the separate Phase 2 study Autolus describes as pivotal in severe refractory SLE with active lupus nephritis. Its registry lists estimated enrollment of 35 and a primary endpoint measuring complete renal response at month six. It is open-label and single-arm. Autolus reported recruiting in five countries in November and expects data in 2028. The registry estimates primary completion in August 2028. The six-month assessment gives the study a fixed point at which to measure kidney response. In a single-arm trial, baseline disease severity, concurrent care and the handling of missing data all matter when interpreting the result. LUMINA trial record · Kidney Week trial-in-progress abstract · Autolus November clinical outlook.

The company announced the FDA’s RMAT designation in systemic lupus erythematosus and lupus nephritis on September 9. A development designation can facilitate interactions with regulators. The approval package for active lupus nephritis depends on sufficient evidence in those patients, including how renal changes evolve and whether the risks of individualized cell therapy are justified. The safety and remission evidence in adult leukemia cannot answer those questions for an autoimmune indication. September designation announcement · Current U.S. product indication.

06 What to follow beyond the lupus and leukemia launch

The December ASH presentations span two diseases and two stages of evidence. The adult leukemia presentation looks at measurable residual disease (MRD), which refers to cancer still detectable with sensitive tests, and recovery from low blood counts in the first three months after obe-cel. The November abstract described deepening MRD response after the first month. This is additional analysis of adult leukemia patients from FELIX, rather than evidence in a new approved population. A separate meeting abstract addresses the agreement of two ways of monitoring the treatment afterward. That measurement study has a different question from whether patients remain in remission. November 4 abstracts · Official December 12 schedule.

ALARIC studies relapsed or refractory systemic light-chain amyloidosis, in which abnormal protein deposits can impair organ function. University College London is the academic sponsor. The November 4 preview said all four patients in the initial group treated with the BCMA-directed CAR T-cell product D8 alone achieved a complete hematologic response at the early cutoff, with median follow-up of five months. The poster scheduled for December 12 addresses the broader trial. The four early observations belong to the D8-alone group, while AUTO8, which adds a CD19 CAR to D8, is the other approach under study. Hematologic response describes control of the abnormal protein-producing cells. Improvement in kidney or heart function and durability require additional evidence and follow-up. Early abstract and December poster · ISRCTN study record · Academic study announcement.

CATULUS is another route for obe-cel, in children with relapsed or refractory disease. The registry distinguishes a wider Phase 1b/2 program that includes pediatric B-cell precursor ALL and aggressive mature B-cell non-Hodgkin lymphoma. The November 13 registry shows estimated enrollment of 30, and Autolus’s April presentation identifies 30 as the Phase 2 target. At the December 2025 ASH meeting, the company reported initial Phase 1 pediatric leukemia findings from the open-label study. Of 22 evaluable participants, 21 achieved remission, including 20 complete responses, with median follow-up of 8.8 months. Grade 3 or higher CRS and ICANS were each reported in 8.7% of the 23 treated participants. The FDA granted Regenerative Medicine Advanced Therapy designation for the pediatric leukemia indication in October 2025. Autolus expects Phase 2 pediatric leukemia data by year-end 2027. The current U.S. AUCATZYL indication is for adults. Changes in safety and clinical outcomes in younger patients need their own evidence. November 13 registry update · April trial presentation · December 2025 Phase 1 report · Pediatric FDA designation · Company data timeline · Marketed U.S. indication.

In refractory progressive multiple sclerosis, BOBCAT is a Phase 1 study. In May Autolus expected an initial BOBCAT update at year-end 2026. Its August presentation gave the first quarter of 2027 for preliminary results. In November it set an October 2027 presentation to obtain longer observation, expecting at least 12 months of follow-up in its first 12 treated patients and data on up to 24 overall. The ECTRIMS congress is scheduled for October 5–8, 2027, in Vienna. The registry identifies a longer estimated schedule through primary completion in August 2029. Disability and progression can take time to assess, and an initial presentation can be informative about feasibility and safety before stable longer-term clinical effects can be measured. Company rationale for moving the BOBCAT presentation · May timing · August timing · Registered study schedule · ECTRIMS event dates.

The November corporate presentation also notes physician interest in investigator-sponsored studies for first-line ALL. First-line disease and relapsed or refractory disease require different clinical comparisons, which would affect any expansion beyond the current label. November development presentation · November conference discussion.

These programs place different demands on the organization. A specialist leukemia center may already have experience with CAR T-cell care and financing. Kidney and neurological programs would need evidence suited to different clinical teams and treatment choices. A successful study might create a chance to work with partners, but much of the cost of providing a broader service would arise before it could contribute materially to sales. Autolus’s present cohort sizes and timetable put the next clinical question at the program level, while operating cash and credit conditions remain company-wide. Pipeline and funding risk factors · Company clinical program list.

07 Product margins and the operating statement

Autolus recorded $74.318 million in net product revenue in 2025, its first year of sales in the United States. In 2026 the company added sales in the United Kingdom, so growth across years reflects both rising U.S. use and a second market. The September product figure was above the year-earlier quarter and below the $45.672 million reported for the June quarter. Treatment-center expansion helps explain the year-over-year increase. Quarter-by-quarter sales depend on how many patients complete treatment during each reporting period. 2025 audited product revenue · June quarterly report · September quarterly report.

U.S. dollars in thousands, except per-share amountsQ3 2026Q3 20259M 20269M 2025
Net product revenue41,23821,144113,12851,049
License revenue—501750
Total net revenue41,23821,194113,14551,099
Cost of sales(17,927)(28,643)(62,963)(71,039)
Research and development, net(30,900)(27,892)(80,008)(82,056)
Selling, general and administrative(35,946)(36,280)(117,060)(96,082)
Operating loss(43,535)(71,621)(146,886)(198,078)
Net other income or expense(12,045)(6,965)(18,075)4,037
Income tax benefit or expense489(532)(839)(3,155)
Net loss(55,091)(79,118)(165,800)(197,196)
Net loss per ordinary share, basic and diluted(0.21)(0.30)(0.62)(0.74)

At the reported product revenue and cost of sales, the quarter produced $23.311 million in product gross profit, a Merlintrader calculation. On November 10, Autolus reported gross margins of 57% for the quarter and 44% for the first nine months. Manufacturing cost per batch fell as volume and utilization improved. The quarter also included $1.9 million of inventory write-downs and $1.6 million of third-party royalties, compared with $4.3 million and $0.6 million respectively in the same quarter in 2025. Some variable costs rise with sales, while changes in write-downs can depend on periods of uneven demand. Operating statement and cost of sales discussion · Published gross margin calculation.

The margin already benefits from some supplies expensed before approval. Autolus estimated that September cost of sales would have been about $0.5 million higher if it had included those previously expensed inventories. The analogous figure for the prior-year quarter was $2.3 million. That adjustment concerns when costs were recognized. It appears alongside a separate operating improvement from better use of facilities and lower write-downs. Future margins will reflect the cost of replacing earlier supplies as well as the scale of production. Prior-expensed inventory and utilization discussion.

The product margin sits above selling, general and administrative spending and development costs. Autolus reported higher third-quarter clinical and manufacturing support costs for its studies, partly offset by lower personnel costs. Its November presentation showed a longer-term peak product gross margin expectation of 65% to 70%. Consolidated cash flow also reflects the rest of the pipeline, financing obligations and corporate working capital. Operating expenses · Company presentation, peak margin expectation.

Some secondary reports state that at the November 17 conference, Chief Executive Officer Christian Itin discussed reaching that margin range and positive cash flow for the acute leukemia business around 2028, and initial first-line study results from MD Anderson Cancer Center around the end of 2027. This account is not confirmed by a primary filing; readers can verify it in the reports linked here. Conference event and webcast · Secondary report (minor site).

The November 10 annual product revenue outlook is $150 million or more, following August guidance of $140 million to $150 million. Actual product revenue through September was $113.128 million. Reaching the new minimum would require $36.872 million of fourth-quarter product revenue, a Merlintrader calculation from the published threshold and year-to-date sales. Actual fourth-quarter results will reflect completions, reimbursements and the mix between the markets already launched. August guidance · New outlook · Nine-month results.

08 Cash use, collections and the funding forecast

At September 30, cash and cash equivalents were $245.405 million and marketable securities were $2.972 million. Together they were $248.377 million, a Merlintrader calculation consistent with the company’s rounded $248.4 million disclosure. Separately classified restricted cash of $1.497 million is outside that total. The combined cash and securities balance was $201.630 million at June 30 and $300.710 million at December 31, 2025, calculated from the cash and securities balances in the respective filings. September was higher than June after the first credit tranche and lower than December after operating expenditures during the year. September and December balance sheets · June balance sheet · Management’s liquidity explanation.

Operating cash use decreased over the first nine months compared with 2025. The June report showed use of $90.386 million in the first half of 2026. The difference between that amount and the nine-month statement is $18.532 million for the September quarter, a Merlintrader calculation. The comparable quarter in 2025 used $67.899 million on the same basis. Quarter-to-quarter movement reflects collections, prepaid items and when costs are paid. Separate nine-month investing outflow for property and equipment was $4.848 million. The financing statement includes another $8.088 million of cash payments on future royalty and milestone liabilities. Nine-month cash flow statement · Six-month cash flow statement.

Working capital moved in more than one direction. Accounts receivable were $38.001 million at September 30, down from $44.392 million in June and up from $24.024 million at year-end. Inventory at September was $35.015 million, compared with $33.209 million at year-end. Faster collection can help finance the next quarter’s production, while rebates, credits or delays can draw out the period between delivering a treatment and having cash available. Changes in receivables used $14.002 million of operating cash during the nine months. Balance sheet, cash flow statement and Note 3 · June receivables.

The September cash flow supplement showed $29.120 million of U.K. research and development tax credits received in the first nine months. That includes a $19.0 million partial payment for the accounting period ended December 2023. Autolus continues discussions with the U.K. tax authority on the higher rate it claims for that period. At December 31, 2025, Autolus recorded the receivable for its 2023 claim at the amount available under the ordinary small and medium enterprise scheme. Any remaining amount depends on the outcome of the discussions. The cash receipts help fund operations, while sales in the two commercial markets are a separate measure of product demand. Cash flow supplement and Note 18.

In the management discussion of the September 10-Q, Autolus expects existing resources, up to $25 million available under the optional second credit tranche, and expected AUCATZYL sales to fund planned operating expenses and capital expenditure for at least 12 months from issuance of the financial statements. It relies on the expected operating plan, including higher sales and gross margin, cost reductions and the timing of tax receipts. The November release gives a longer projection into the second quarter of 2028, with projected product revenue and the first two credit tranches. A change in replacement inventory costs, collections or lending access would change the time available. Note 1 and liquidity discussion · November operating runway forecast.

09 Perceptive credit terms and collateral

On July 30, 2026, Autolus entered its senior secured notes facility with Perceptive Credit Holdings V, LP as administrative agent. It received funding for $75 million of principal at closing. The September balance sheet carried $66.816 million after the unamortized discount and issuance costs. The carrying amount reflects the allocation to the warrant and the timing of recognition of the issuance costs, while the notes oblige the borrower to pay principal. Financing closing and agreement exhibits · Note 14, carrying amount and allocation.

TrancheMaximum principalAvailability under the disclosed agreement
First$75 millionIssued and funded July 30, 2026
Second$25 millionAvailable at the company’s option under the agreement through January 30, 2027
Third$75 millionSubject to consolidated net revenue conditions before July 31, 2028
Fourth$75 millionSubject to consolidated net revenue conditions before January 31, 2030

The $250 million ceiling spans all four rows. The November quarterly filing had disclosed the initial borrowing and access to the optional second tranche. The third and fourth tranches each have a separate revenue test. As sales grow, Autolus could have more borrowing options without needing them at the same level. Slow sales could have the reverse effect on both the operating plan and conditional borrowing. Note 14 and November liquidity disclosure.

Interest is payable monthly and uses the greater of one-month term Secured Overnight Financing Rate (SOFR) and 3.50%, with a margin of 6.75% to 7.25% tied to trailing consolidated net revenue. The contractual July 30, 2031 maturity is the scheduled principal payment date. Early redemption may require a premium of 1% to 8%. The default rate can increase by four percentage points in the circumstances specified in the agreement. Note 14, interest and maturity · Purchase agreement and guaranty.

The notes are backed by a first-priority security interest over substantially all assets of the company and relevant subsidiary guarantors, subject to customary exceptions. The facility includes minimum consolidated net revenue tests and a minimum liquidity amount ranging from $12.5 million to $50 million depending on the contract’s consolidated net revenue and market capitalization thresholds. A default can let lenders accelerate principal and interest and exercise remedies over collateral under the specified terms. Holding cash to meet the applicable covenant affects how much is available for ordinary spending. Financing covenants and related risk factor.

10 Revenue shares and other obligations

Total liabilities were $495.663 million and shareholders’ equity was $27.396 million at September 30. The liability total includes $40.600 million of current and $252.700 million of noncurrent obligations associated with future royalties and milestones. Those figures measure estimated future contract-linked payments. The senior secured debt and operating leases appear on separate balance-sheet lines. Current lease liabilities were $4.044 million and noncurrent lease liabilities were $77.013 million. Balance sheet and Notes 13–15.

Autolus’s Note 13 rollforward began the year at $280.200 million. It recorded $35.278 million of accrued interest expense on those liabilities and a negative $14.090 million cumulative catch-up adjustment. The company made $8.088 million of revenue-share payments, leaving the reported $293.300 million balance. The adjustment reflects revisions to the estimate of future obligations. Actual payments use cash when remitted and the cash flow statement classifies them as financing. Note 13 rollforward and statement of cash flows.

The collaboration with BXLS V – Autobahn L.P., part of Blackstone, provided payments at signing, during development and after U.S. approval. The annual filing records $150 million received in total by December 31, 2024. Autolus agreed to a mid-single-digit share of eligible sales and specified sales milestones, subject to an aggregate cap. The September carrying amount for the Blackstone collaboration was $248.2 million. Its economic rights under that contract continue separately from Blackstone’s ordinary share and warrant positions. Annual Blackstone agreement disclosure · September related-party note.

BioNTech paid $40 million upfront for an interest in future obe-cel product revenue. The low-single-digit share can increase to a mid-single-digit share at BioNTech’s election in return for milestones of up to $100 million in aggregate upon specified regulatory events for new indications. The September carrying amount tied to BioNTech was $45.1 million. A new product indication can expand revenue while also changing which contract payments might come due. Notes 13 and 21 on BioNTech.

Other obligations affect costs or access to commercial supplies. Autolus’s 2025 annual report describes regulatory milestone payments to University College London Business under its license: £10 million, paid after U.S. approval, and £6 million, paid after European marketing approval. The September filing reports that related royalties and other amounts continued to be paid or accrued, and that further milestones may come due. A separate agreement with AGC has a €25 million minimum purchase commitment over a specified five-year period for supplies and services. These obligations are subject to their own performance and time conditions. UCL Business license and paid regulatory milestones · Note 18 on commitments.

11 Outstanding equity, options and warrant terms

The November 9 ordinary share figure matches the September 30 period-end balance. The December 31, 2025 count was 266,143,286. The September balance sheet lists 490,909,783 authorized ordinary shares. A potential share can appear in a warrant, equity award, plan reserve or registration before it becomes issued and outstanding. These measures answer distinct questions about ownership today and how ownership could change. Cover, capital accounts and equity plans.

The September filing reports 35,951,526 outstanding share options, 4,007,421 unvested restricted stock units (RSUs) and warrants covering 6,765,306 ADSs. The option note identifies 19,936,804 options as exercisable at period-end. The September tally of 46,724,253 potential shares is excluded from diluted loss per share because their effect would be antidilutive under the reported loss. The number ultimately placed into circulation depends on vesting, exercise and, for some instruments, contingent financing. Notes 5 and 17, share counts and award activity.

The warrant on up to 3,265,306 ADSs issued to Blackstone had a contractual exercise price of $7.35 and expired without exercise on November 6. It was included in the September tally. The separate Perceptive warrant covers up to 3.5 million ADSs at a contractual exercise price of $1.9314 and expires on July 30, 2036. The September 22 prospectus registered possible resale of shares underlying that warrant. Exercise by the holder and later resale are different events. Autolus would receive the exercise price for a cash exercise and allows cashless exercise under the agreement, while it receives no proceeds from resales. Note 16, Blackstone and Perceptive warrants · September resale prospectus.

Funding of each of the third and fourth credit tranches would trigger a separate warrant for up to 2.5 million ADSs, subject to adjustments. Their contract sets the exercise price using a volume-weighted average before issuance and keeps the July 30, 2036 expiration date. Each of those warrants comes into being if the corresponding later tranche is issued. The initial Perceptive warrant was already included in September’s outstanding warrant figures. Credit and warrant exhibits · Note 14.

A Form S-3 filed in April registered up to $150 million of ordinary shares or ADSs, debt securities and warrants. The U.S. Securities and Exchange Commission declared that shelf effective on May 5. It gives Autolus a way to offer securities in the future. An additional April shelf covered securityholder resales, including ADSs underlying the Blackstone warrant that later expired. The separate September prospectus covers the Perceptive warrant. April primary registration · Notice of effectiveness · April resale registration.

On November 13, Autolus used Form S-8 to register 10,653,613 more ordinary shares represented by ADSs for its 2018 Equity Incentive Plan. The reserve had increased automatically on October 1 under the plan. The company separately reported October 21 inducement grants to 15 employees, giving them options over 75,400 ADSs and 129,310 RSUs under the separate 2025 plan. Registration adds capacity, while awards represent a potential transfer of equity under their terms. Both can affect longer-term ownership without the same immediate changes in issued shares. Form S-8 · November 3 announcement of October awards · Note 17, separate compensation plans.

12 Ownership filings and liquidity on Nasdaq

The November 10 Schedule 13D amendment reported a direct position of 20,485,611 ADSs held by BXLS V – Autobahn L.P., or 7.6% using the filer’s stated denominator. That denominator is 269,662,540 from the September prospectus and assumes issuance of all 3.5 million shares underlying the Perceptive warrant. The same prospectus gives 266,162,540 ordinary shares actually outstanding on August 10. The amendment attributes the beneficial-ownership change to expiry of the Blackstone warrant. The same position is attributed through related Blackstone entities. Ownership amendment, Items 1, 5 and 6 · September prospectus and pro forma share count.

The November 16 MAK amendment identifies 30,528,859 ADSs and 11.5% in its aggregate figures for the September 30 event, using the company’s November 9 outstanding count in the filing footnote. The figures for the fund and related reporting persons overlap. Armistice Capital, LLC and Steven Boyd reported a common position of 13,750,000 ADSs, or 5.17%, as of September 30 in their November 16 filing. Qatar Investment Authority reported 9,184,404 ADSs, or 3.5%, for the same event date in its November 12 amendment and stated it had ceased to own more than 5%. MAK Schedule 13G amendment, aggregate and Item 4 · Armistice amendment · Qatar Investment Authority amendment.

In its November 12 interim results, Syncona reported a 9.2% shareholding in Autolus in its portfolio table for the period ended September 30, measured as its ownership stake at the point its current commitments are fully invested. That basis differs from the basis for the Schedule 13G percentages. Autolus’s March 1 ownership table listed 33,333,333 ADSs, or 12.5%, for BioNTech. The September filing states BioNTech remained above 10% and had not exercised its right to nominate a board member. PPF’s August 28 amendment reports 14,782,275 ordinary shares, or 5.6%, held by PPF IM after a transfer within the group that left ultimate beneficial ownership unchanged. Syncona interim results · Autolus annual ownership table · September related-party note · PPF ownership amendment.

The September 3 Form 4 for U.S. Chief Commercial Officer Cintia Piccina reported conversion of RSUs into 20,000 ADSs on September 1 under code M, and a separate September 2 sale of 6,713 ADSs under code S. The filing showed 13,287 directly owned after those entries. The Form 144 on September 2 described the proposed transaction, while the Form 4 reports execution. A June compensation grant to director William D. Young reported on July 1 used code A. Piccina Form 4 · September 2 notice · Young Form 4.

Nasdaq showed 8,628,641 shares short at the October 30 settlement, with average daily volume of 1,825,559 shares and 4.73 days to cover. On October 15 the corresponding figures were 9,065,436 shares short, 1,772,779 average daily volume and 5.11 days. The decline reflects fewer reported shorts and higher average volume. These are settlement observations and the ratio uses average historical trading volume. The next scheduled publication is November 24 for the November 13 settlement. Nasdaq short interest · Financial Industry Regulatory Authority publication calendar.

13 Operating risks, governance and valuation

Autolus is changing how it reports in the United States. It did not qualify as a foreign private issuer at its June 30 test date and says the change becomes effective January 1, 2027. It was already using certain domestic reporting forms voluntarily. Full application of domestic issuer requirements adds federal proxy rules, Regulation Fair Disclosure and short-swing profit requirements for relevant insiders under Section 16 of the Exchange Act. Autolus expects additional legal, accounting, insurance and related costs. The company remains incorporated in England and Wales. Reporting status and related risk factor.

The September quarterly filing reported no current material legal proceedings. Its commitments note reports no litigation reserves at September 30, 2026, or December 31, 2025. The U.K. tax-credit discussions involve a separate financial uncertainty. The same filing describes an April workforce reduction that was substantially completed by the end of September. The plan covered about 13% of the workforce and included measures begun in the second half of 2025. In April the company projected annualized operating expense savings of about $15 million beginning in 2027. It reports $5.094 million of severance and termination costs incurred in the first nine months and $0.270 million of remaining liability at September 30. The economic benefit of restructuring depends on savings outrunning new costs needed for the commercial and clinical programs. Notes 18 and 20 and legal proceedings · April restructuring outlook.

Valuation starts with what the existing product can finance under different assumptions for utilization, collections and manufacturing cost. Future margins must account for the changing cost of supplies formerly recorded as research expenses and ongoing commitments. Broader indications create separate opportunities with trial risk and different commercial costs. Commercial economics and risk factors · Company commercial targets.

Operating needs draw on the same resources as lender interest, cash royalties, future milestones and supply commitments. If sales and collections meet the operating plan, the business could reduce reliance on outside capital. If growth falls short, eligibility for borrowing and minimum liquidity requirements can reinforce pressure even as an approved product continues to sell. The time and financing needed for new trials should be evaluated alongside the existing leukemia business’s operating performance. Credit and collaboration obligations · Management runway assumptions.

Merlintrader Health Score · $AUTL

2.90out of 5
Balance sheet and runway · 30%2.5 / 5

September cash and securities of $248.4 million include the July borrowing. The company’s runway forecast depends on sales and the optional second tranche, and partner obligations continue. Liquidity and liabilities · Company funding outlook.

Catalysts · 30%3.0 / 5

The December 12 meeting brings adult leukemia follow-up and early amyloidosis observations. Major pediatric, multiple sclerosis and lupus nephritis updates are on later timelines. December program · Development calendar.

Dilution · 20%2.5 / 5

Expiry of Blackstone’s warrant removed one potential equity claim, while the initial Perceptive warrant, conditional warrants and employee awards can still add shares. Notes 14, 16 and 17 · New plan capacity.

Trading liquidity · 10%3.5 / 5

The ADSs trade on the Nasdaq Global Select Market. October 30 short interest represented 4.73 days at the reported average volume of 1,825,559 shares. Listing on filing cover · Nasdaq data.

Execution · 10%4.0 / 5

Gross margin reached 57% in the September quarter and the company raised the annual product revenue outlook to $150 million or more. Continued operating losses and the decline in sales versus June leave commercial economics to be demonstrated over more quarters. Quarterly results · June comparison.

Reassessed November 19, 2026. Merlintrader calculation: 2.5 × 30% + 3.0 × 30% + 2.5 × 20% + 3.5 × 10% + 4.0 × 10% = 2.90 out of 5.

AUTL red flags

  • Completed treatments and collections drive cash. Recognized revenue follows completion of the treatment course. Credits can apply in certain cases where treatment is interrupted. Distribution and accounting.
  • The facility gives lenders a senior claim. The secured notes carry a first-priority claim on substantially all pledged assets, with exceptions, alongside continuing royalty and milestone obligations. Credit risk · Royalties.
  • Commercial safety remains consequential. The prescribing information carries warnings for severe events and secondary hematological malignancies. Marketed safety evidence.
  • Lupus evidence remains limited. The November result comes from a small Phase 1 follow-up group. LUMINA tests a defined kidney response at six months. Trial populations and endpoints.

AUTL Stock FAQ: Autolus Therapeutics plc Questions Answered

When is the next Autolus Therapeutics clinical update?

Autolus is scheduled to present results on December 12, 2026, at the hematology meeting in New Orleans. An adult leukemia presentation and an early amyloidosis poster have separate populations and will be presented on the same day. Autolus abstract announcement · Meeting organizer.

What has the FDA approved for Autolus?

The FDA approved AUCATZYL for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia on November 8, 2024. Autolus is still studying obe-cel in lupus and pediatric leukemia as of November 19, 2026. U.S. approval · Development portfolio.

How much does Autolus hold in cash and securities?

Autolus reported $248.4 million of cash, cash equivalents and marketable securities at September 30, 2026. Its November 10 funding outlook includes projected product sales and the first two tranches of its credit facility. Results and outlook · September balance sheet.

What could dilute holders of AUTL shares?

On November 13, 2026, Autolus registered additional shares for its 2018 incentive plan. Separate potential dilution can come from the Perceptive warrant, conditional warrants if later tranches are funded and eventual settlement of employee awards. Incentive-plan registration · Equity and financing terms.

When did Autolus Therapeutics report its latest earnings?

Autolus announced results for the September quarter on November 10, 2026, and filed its Form 10-Q that day. The company’s calendar had given no date for the next results release as of November 19, 2026. Results exhibit · Form 10-Q · Company event calendar.

What does Autolus Therapeutics do?

Autolus describes itself in its November 10, 2026, financial report as a commercial cell-therapy company. It markets AUCATZYL in the United States and United Kingdom and develops additional uses in cancer and autoimmune disease. Business and development programs.

How much has Autolus drawn on its Perceptive facility?

Autolus drew the first $75 million tranche at the July 30, 2026, closing. The company’s September filing describes a separately available $25 million tranche and two further tranches subject to revenue conditions. Closing disclosure · Note 14 on availability and covenants.

Primary sources and research literature

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $AUTL or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology and pharmaceutical companies carry clinical, regulatory, commercial and financing risk, including dilution, and readers can lose capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.